Last night’s Q2 results were in line with expectations. Net portfolio fair value increased by SEK8.3m during the quarter to SEK180.9m, mainly as a result of investments in Modus Therapeutics. Cash, cash equivalents & ST investments at period-end stood at SEK189.1m. In addition, we have updated forecasts following the set-off equity issue in April (the uptake of which was modest at SEK67m). Although we look forward to a wealth of Phase II trial read-outs in 2018, we remain concerned about the out ....
30 Aug 2017
N+1 Singer - Karolinska Development AB - Q2 results; forecasts updated
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Karolinska Development AB - Q2 results; forecasts updated
Karolinska Development AB Class B (0P3C:LON) | 0 0 5.4% | Mkt Cap: 369.6m
- Published:
30 Aug 2017 -
Author:
Dr Jens Lindqvist -
Pages:
4
Last night’s Q2 results were in line with expectations. Net portfolio fair value increased by SEK8.3m during the quarter to SEK180.9m, mainly as a result of investments in Modus Therapeutics. Cash, cash equivalents & ST investments at period-end stood at SEK189.1m. In addition, we have updated forecasts following the set-off equity issue in April (the uptake of which was modest at SEK67m). Although we look forward to a wealth of Phase II trial read-outs in 2018, we remain concerned about the out ....